advertisement
Abstract #106037 Published in IGR 23-3
Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS)
Montesano G; Ometto G; King A; Garway-Heath DF; Crabb DPAmerican Journal of Ophthalmology 2023; 246: 42-50
PURPOSE: to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS). DESIGN: Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial. METHODS: A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (n = 227) or medication in their index eye (n = 226) and followed-up for 2 years with 2 24-2 VF tests at baseline, 4, 12, and 24 months. Data were analyzed for participants with a reliable VF (false positive rate < 15%) at baseline and at least 2 other time points. Average difference in rate of progression (RoP) was analyzed using a hierarchical Bayesian model. Time for each eye to progress from baseline beyond specific cut-offs (0.5, 1, 1.5, and 2 dB) was compared using survival analysis. RESULTS: This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was -0.59 [-0.88, -0.31] dB/year in the medication first arm and -0.40 [-0.67, -0.13] dB/year in the trabeculectomy first arm. The difference was not significant (Bayesian P-value = .353). More eyes progressed in the medication first arm, but this difference was not significant. CONCLUSIONS: There was no significant difference in the average RoP at 2 years.
From City, University of London, Optometry and Visual Sciences, London, UK (G.M., G.O., D.P.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK (G.M., D.F.G-H.).
Full article